Novartis’ former chief medical officer John Tsai has returned to a senior position in biopharma, taking the role of chief executive of UK start-up Forcefield Therapeutics.
Ionis Pharma is preparing to file for regulatory approval of its experimental therapy olezarsen for familial chylomicronaemia syndrome (FCS) in the US and Europe after the
Takeda has bolstered its neuroscience pipeline by licensing drug candidates from California biotech AcuraStem targeting PIKfyve, which is gathering attention as a drug tar
Novo Nordisk has paid $60 million to partner Valo Health on a project that will apply the US start-up’s artificial intelligence-powered drug discovery engine to find new t
Novartis is preparing to file for approval of its radioligand therapy Lutathera as a first-line treatment for people with rare neuroendocrine tumours after it showed a ben
A combination of Astellas and Seagen’s Padcev with MSD’s Keytruda has significantly improved survival compared to chemotherapy in previously untreated patients with advanc